One Dose Does Not Fit All: The Pharmacogenomic Gap Quietly Undermining Precision Medicine
The phrase "precision medicine" has become one of biotechnology's most frequently invoked promises. It evokes a future in which therapies are calibrated to the individual — tuned to a patient's genetic architecture, metabolic profile, and physiological context rather than derived from the averaged responses of trial cohorts. Yet for the millions of Americans who fill prescriptions each year, that future remains largely theoretical. The standard of care, in most clinical settings, still begins and ends with a single printed dose on a drug label — a number that was never designed to reflect who they are.
The consequences of this mismatch are neither trivial nor rare. Adverse drug reactions account for an estimated 100,000 deaths annually in the United States and contribute to more than 1.5 million preventable injuries, according to figures cited by the Institute of Medicine. A significant proportion of those events trace back not to the wrong drug, but to the wrong dose — administered to a patient whose biology was never adequately represented in the clinical trial that produced the label in the first place.
The Architecture of the Average
To understand why dosing precision lags so far behind genomic science, it is necessary to examine how drug approval pathways are constructed. The FDA's standard framework for evaluating a new therapeutic relies on randomized controlled trials designed to demonstrate efficacy and safety across a defined patient population. That population, by statistical necessity, is treated as a unit. The dose selected for approval is the one that produced the most favorable risk-benefit profile across the aggregate — not the dose that would be optimal for any given individual within it.
This approach is not arbitrary. Population-level evidence is the most defensible scientific foundation for regulatory decisions affecting millions of patients. The challenge arises when that foundation is then applied uniformly, without adjustment, to people whose underlying biology may diverge substantially from the trial average. Genetic polymorphisms in drug-metabolizing enzymes, variations in renal and hepatic function, differences in body composition, and the compounding effects of co-administered medications can each alter drug exposure by orders of magnitude. When those variables go unaccounted for, the printed label becomes, at best, an approximation — and at worst, a source of systematic harm.
What Pharmacogenomics Already Knows
The scientific literature on pharmacogenomics is not nascent. Researchers have known for decades that variants in genes encoding cytochrome P450 enzymes — the primary metabolic machinery through which the liver processes most drugs — can render standard doses either dangerously toxic or therapeutically inert, depending on whether a patient is a poor, intermediate, extensive, or ultrarapid metabolizer. For a drug like codeine, which must be converted to morphine to produce its analgesic effect, an ultrarapid metabolizer may experience life-threatening respiratory depression at a dose that barely touches a poor metabolizer.
The FDA has, in some cases, incorporated pharmacogenomic information into drug labeling. Boxed warnings exist for certain antidepressants, anticoagulants, and oncology agents where genetic testing can meaningfully inform prescribing. The anticoagulant warfarin, for instance, carries labeling that acknowledges the influence of CYP2C9 and VKORC1 variants on dosing requirements. Yet for the vast majority of approved drugs, pharmacogenomic data — even where robust and clinically actionable — does not translate into mandatory testing requirements or individualized dosing guidance. It appears, if at all, as advisory language that most clinicians lack the time, training, or reimbursement incentive to act upon.
The Reimbursement Barrier and the Clinical Inertia Problem
Even where pharmacogenomic testing is scientifically justified, the pathway from laboratory insight to clinical practice is obstructed by structural barriers that have little to do with science. Genetic testing for drug metabolism is inconsistently covered by insurers, and when it is covered, the results are frequently not integrated into electronic health record systems in ways that prompt actionable prescribing decisions. Clinicians operating under time pressure in high-volume settings are rarely equipped to interpret a pharmacogenomic report, let alone translate it into a dosing adjustment that deviates from label guidance.
The regulatory framework compounds this inertia. Because the FDA approves drugs at specific doses with specific indications, prescribers who deviate from label guidance — even when pharmacogenomic evidence clearly supports doing so — assume a degree of medicolegal exposure that most are unwilling to accept. The label, in other words, functions not merely as scientific guidance but as a liability boundary. Rebuilding it around individual biology would require not only updated regulatory science but a fundamental renegotiation of how prescribing authority and clinical accountability are structured.
Demographic Blind Spots in Trial Design
The problem extends beyond genetics. Clinical trial populations in the United States have historically skewed toward white male participants, a pattern that creates systematic gaps in dosing data for women, elderly patients, and individuals from non-European ancestral backgrounds. Women metabolize certain drugs differently than men due to hormonal influences on enzyme activity and differences in body composition. Older adults experience progressive declines in renal and hepatic clearance that alter drug exposure across virtually every therapeutic class. Yet dosing labels derived from trials that underrepresented these groups are applied to them without adjustment, embedding demographic bias into the standard of care.
The FDA has taken steps to address representation in clinical trials, and recent legislative pressure has reinforced those efforts. But the downstream problem — that approved labels based on historically narrow populations continue to guide prescribing for demographically diverse patients — remains largely unaddressed. Updating existing labels to incorporate dosing guidance for underrepresented groups requires post-marketing studies that sponsors have limited commercial incentive to conduct.
Toward a Biology-First Labeling Framework
Reforming the system requires confronting a set of entangled challenges simultaneously. Regulatory agencies would need to develop new frameworks for approving dosing ranges rather than fixed doses, with guidance that incorporates pharmacogenomic and demographic modifiers. Clinical decision support tools embedded in electronic health records would need to translate genomic data into actionable prescribing recommendations at the point of care. Reimbursement structures would need to recognize genetic testing as a standard component of medication management rather than an optional diagnostic add-on.
Some researchers and policy advocates have proposed the concept of "pharmacogenomic-informed labeling" as a near-term step — a model in which drug labels are required to disclose known genetic modifiers of drug response, even where mandatory testing is not yet feasible. Others have pointed to the potential of real-world evidence, collected through electronic health records and biobank-linked prescription databases, to generate post-approval dosing data that captures the biological diversity absent from original trials.
None of these solutions is simple, and none can be implemented without confronting the economic and institutional interests that have long benefited from the status quo. But the scientific case for change is no longer speculative. The tools to decode individual drug response exist. The genomic data to act on that knowledge is increasingly accessible. What remains missing is the regulatory and clinical infrastructure to translate that knowledge into the individualized dosing that precision medicine has always claimed to offer — and that patients, for too long, have been promised without receiving.
